Patients with DLBCL, B-Cell Lymphomas, and Follicular Lymphoma: we need your help!
Lymphoma Canada is preparing a submission for the Canadian Agency for Drugs and Technology (CADTH), and its Quebec equivalent INESSS, for an upcoming drug review on lisocabtagene maraleucel, a CAR T-cell therapy for relapsed or refractory diffuse large b-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large b-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B).
If you have one of these lymphomas and have received this treatment, you can help by completing our survey. You can still participate in this survey if you have not received this therapy by sharing your experience with your lymphoma.
The feedback from this survey will provide us with valuable patient input required for the submission. CADTH and INESSS use this information to help them make recommendations regarding funding for new cancer drugs.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
Thank you for your support.
Please share and help us spread the word.